Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 360 from DKK 415 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Expands GLP-1 Ambitions With Completed Liver and Alcohol Use Trial
- Novo Nordisk upgraded to Hold from Underperform at Jefferies
- ESIH, XSDR, HLTH: These ETFs Provide Exposure to Europe’s Top Healthcare Companies
- Novo Nordisk CFO Sells DKK 8.4 Million in Company Shares
- Mixed options sentiment in Novo Nordisk with shares down 1.82%